Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The ‘master-switch’ experimental drug, owned by Astex Pharmaceuticals, could potentially treat a range of cancer types.
21 January, 2013
Crescendo Biologics Limited (Crescendo) announces the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody VH fragments from a transgenic mouse.
16 January, 2013